In a continued effort to enhance healthcare awareness and support for rare diseases, Chonburi Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (‘Novo Nordisk’), hosted the ‘Unlock and Rock Haemophilia’ event. The initiative aimed to raise awareness and strengthen understanding of haemophilia among children, patients, and their families, while engaging the haemophilia community in Eastern Thailand through the Thai Hemophilia Patient Club.
According to the World Federation of Haemophilia’s Global Survey 2023, approximately 200,000 people worldwide live with haemophilia, including more than 2,000 in Thailand. Many face ongoing challenges such as underdiagnosis and limited access to quality healthcare.
The event featured educational sessions led by healthcare professionals, offering guidance on home care and mental support for individuals and families affected by haemophilia. Interactive workshops provided hands-on experience in medication handling, preparing emergency kits, crafting bracelets, and learning suitable exercises – equipping participants with practical tools for effective disease management.
Dr Sureeporn Chinawan, Paediatric Haematology and Oncology Specialist at Chonburi Hospital, emphasised the event’s role in showcasing the strong partnership between the hospital and Novo Nordisk, driven by a shared mission to ‘unlock barriers and empower people with haemophilia to live life to the fullest.’
Dr Jiranuch Thammakumpee, Deputy Director of Chonburi Hospital, added, ‘Empowering individuals living with haemophilia and their families through interactive education is vital. We remain committed to providing the resources and support necessary to enhance patient care in Eastern Thailand. This event not only raises awareness but also builds a compassionate, informed community.’
Aligned with both organisations’ patient-centric approach, the event also featured heartfelt testimonies from people living with haemophilia, sharing their real-life experiences in overcoming daily challenges.
Ms Selina Christodoulakis, Director of the Rare Disease Business Unit at Novo Nordisk Pharma (Thailand), noted: ‘At Novo Nordisk, we believe that understanding and awareness are key to improving the lives of those affected by rare diseases. Events like ‘Unlock and Rock Haemophilia’ bridge the gap between education and empowerment, helping patients and families build confidence in managing their conditions.’
Ultimately, ‘Unlock and Rock Haemophilia’ was more than an awareness campaign – it created a supportive space for patients and families to connect, share, and strengthen their confidence in living well with haemophilia.
About Novo Nordisk:
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube